For a cancer to exist in the body it must be able to evade destruction by the immune system. Some cancers do this by triggering signals that inhibit immunologic activity. Medicines that interfere with this type of signalling have now led to dramatic tumor regressions for many cancer patients. My work is focused on identifying and blocking signals that instruct the immune system to tolerate cancer.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Danny Khalil discloses the following relationships and financial interests:
Merck Sharp & Dohme
Intellectual Property Rights
PsiOxus Therapeutics Ltd
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.